psoriatic arthritis Archives -

Janssen J&J Johnson and Johnson pharmaceutical companies

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment

NICE makes J&J’s Tremfya more accessible in England and Wales

https://pharmaphorum.com/news/nice-makes-jjs-tremfya-more-accessible-in-england-and-wales/

News/ News/ R&D

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

Richard Staines AbbVie, Humira, inflammatory diseases, psoriatic arthritis, Skyrizi 0 Comment

AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

https://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/

News/ News/ Sales and Marketing

J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay

Richard Staines AbbVie, Eli Lilly, Johnson & Johnson, Pfizer, psoriatic arthritis, Sun Pharma, Tremfya 0 Comment

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23

J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay

https://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/

Market Access/ News/ News/ News/ R&D/ Top stories

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

Phil Taylor AbbVie, Cosentyx, Eli Lilly, Humira, immunology, Novartis, psoriatic arthritis, Taltz 0 Comment

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/

Market Access/ News/ News

J&J filing aims Tremfya at crowded psoriatic arthritis market

Phil Taylor fda, filing, immunology, Johnson & Johnson, psoriatic arthritis, Tremfya 0 Comment

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication,

J&J filing aims Tremfya at crowded psoriatic arthritis market

https://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/

News/ News/ R&D

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Phil Taylor Humira, Lilly, psoriatic arthritis, Taltz 0 Comment

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

https://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/

News/ News/ R&D

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Richard Staines AbbVie, ankylosing spondylitis, Cosentyx, EULAR, Novartis, psoriatic arthritis, rheumatology 0 Comment

Swiss pharma hopes to bounce back from Q1 sales disappointment

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

https://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/

News/ News/ R&D/ R&D

Novartis tests Cosentyx against Humira and biosimilars

Richard Staines AbbVie, biosimilars, Novartis, psoriatic arthritis 0 Comment

Trials will cover psoriatic arthritis and ankylosing spondylitis

Novartis tests Cosentyx against Humira and biosimilars

https://pharmaphorum.com/news/novartis-tests-cosentyx-humira-biosimilars/

News/ US

Pfizer’s Xeljanz approved in psoriatic arthritis

Richard Staines Celgene, inflammatory diseases, Pfizer, psoriatic arthritis 0 Comment

Xeljanz is first JAK inhibitor approved in psoriatic arthritis

Pfizer’s Xeljanz approved in psoriatic arthritis

https://pharmaphorum.com/news/pfizers-xeljanz-approved-psoriatic-arthritis/

Trending

psoriatic arthritis

Login